Localisation of phosphorylated mTOR expression is critical to tumour progression and outcomes in patients with endometrial cancer

European Journal of Cancer

Volumn 46, Issue 18, 2010, Pages 3445-3452

  Yoshida, Yoshio ^a   Kurokawa, Tetsuji ^a   Horiuchi, Yuko ^a   Sawamura, Yoko ^a   Shinagawa, Akiko ^a   Kotsuji, Fumikazu ^a  

^a UNIVERSITY OF FUKUI   (Japan)

Author keywords

Endometrial endometrioid adenocarcinoma; Location; Outcome; Phospho Akt; Phospho mTOR

Indexed keywords

CARBOPLATIN; MAMMALIAN TARGET OF RAPAMYCIN; PACLITAXEL; PROTEIN KINASE B;

ABDOMINAL HYSTERECTOMY; ADJUVANT THERAPY; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER PATIENT; CANCER RELAPSE; CELL NUCLEUS; CYTOPLASM; DISEASE FREE SURVIVAL; ENDOMETRIAL ENDOMETRIOID ADENOCARCINOMA; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CARCINOMA; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; RADICAL HYSTERECTOMY; RISK FACTOR; SALPINGOOOPHORECTOMY; TREATMENT OUTCOME; TUMOR GROWTH;

ADULT; AGED; AGED, 80 AND OVER; DISEASE PROGRESSION; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; PHOSPHORYLATION; PROGNOSIS; TOR SERINE-THREONINE KINASES; UTERINE NEOPLASMS;

EID: 78649630421     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2010.09.004     Document Type: Article

References (30)

1. W.T. Creasman, F. Odicino, and P. Maisonneuve Carcinoma of the uterus uteri Int J Gynecol Oncol 95 1 2006 S105 S143
2. D.S. Mcmeenkin, K.M. Alektiar, P.J. Sabbatini, and R.J. Zaino Corpus: epithelial tumors R.R. Barakat, M. Markman, M.E. Randall, Principles and practice of gynecologic oncology 5th ed. 2009 Lippincott Williams & Wolters Kluwere Baltimore 683 733
3. Y. Todo, H. Kato, and M. Kaneuchi Survival effect of para-aortic lymphadenectomy in endometrial cancer (SEPAL study): a retrospective cohort analysis Lancet 375 2010 1165 1172
4. M. Ray, and G. Fleming Management of advanced-stage and recurrent endometrial cancer Semin Oncol 36 2009 145 154
5. J.T. Thigpen, J.A. Blessing, and P.J. DiSaia A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study J Clin Oncol 12 1994 1408 1414
6. F. Calero, E. Asins-Codoner, and J. Jimeno Epirubicin in advanced endometrial adenocarcinoma: a phase II study of the Grupo Ginecologico Espanol para el Tratamiento Oncologico (GGETO) Eur J Cancer 27 1991 864 866
7. F.H. van Wijk, C. Lhomme, and G. Bolis Phase II study of carboplatin in patients with advanced or recurrent endometrial carcinoma. A trial of the EORTC Gynaecological Cancer Group Eur J Cancer 39 2003 78 85
8. A. Lissoni, G. Zanetta, and G. Losa Phase II study of paclitaxel as salvage treatment in advanced endometrial cancer Ann Oncol 7 1996 861 863
9. G.F. Fleming, V.L. Brunetto, and D. Cella Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study J Clin Oncol 22 2004 2159 2166 (Pubitemid 41095150)
10. J.I. Risinger, K. Hayes, and G.L. Maxwell PTEN mutation in endometrial cancers is associated with favorable clinical and pathologic characteristics Clin Cancer Res 4 1998 3005 3010
11. D.A. Altomare, and J.R. Testa Pertubations of the AKT signaling pathway in human cancer Oncogene 24 2005 7455 7464
12. P. Chaudhry, and E. Asselin Resistence to chemotherapy and hormone therapy in endometrial cancer Endocrine-Related Cancer 16 2009 363 380
13. K. Uegaki, Y. Kanamori, and J. Kigawa PTEN-positive and phosphorylated-Akt-negative expression is a predictor of survival for patients with advanced endometrial carcinoma Oncol Rep 14 2005 389 392
14. N. Mori, S. Kyo, and J. Sakaguchi Concomitant activation of AKT with extracellular-regulated kinase 1/2 occurs independently of PTEN or PIK3CA mutations in endometrial cancer and may be associated with favorable prognosis Cancer Sci 98 2007 1881 1888
15. A. Steinbakk, I. Skaland, and E. Gudlaugsson The prognostic value of molecular biomarkers in tissue removed by curettage from FIGO stage 1 and 2 endometrioid type endometrial cancer Am J Obstet Gynecol 200 2009 78.e1 78.e8
16. H. Wahl, S. Daudi, and M. Kshirsagar Expression of metabolically targeted biomarkers in endometrial carcinoma Gynecol Oncol 116 2010 21 27
17. S. Wullschleger, R. Loewith, and M.N. Hall TOR signaling in growth and metabolism Cell 124 2006 471 484
18. S. Darb-Esfahani, A. Faggad, and A. Noske Phospho-mTOR and phospho-4EBP1 in endometrial adenocarcinoma: association with stage and grade in vivo and link with response to rapamycin treatment in vitro J Cancer Res Clin Oncol 135 2009 933 941
19. J.H. No, Y.-H. Jeon, and I.-A. Park Expression of mTOR protein and its clinical significance in endometrial cancer Med Sci Monit 15 2009 301 305
20. FIGO stages - 1988 revision. Gynecol Oncol 1989;35:125-7.
21. S. Nur, L. Chuang, and G. Ramaswamy Immunohistochemical characterization of cancer antigen in uterine cancers Int J Gynecol Cancer 16 2006 1903 1910
22. D.M. Sabatini, R.K. Barrow, and S. Blackshaw Interaction of RAFT1 with gephyrin required for rapamycin-sensitive signaling Science 284 1999 1161 1164
23. O.M. Tirado, S. Mateo-Lozano, S. Sanders, L.E. Dettin, and V. Notario The PCPH oncoprotein antagonizes the proapoptotic role of the mammalian target of rapamycin in the response of normal fibroblasts to ionizing radiation Cancer Res 63 2003 6290 6298
24. R.M. Drenan, X. Liu, P.G. Bertram, and X.F. Zheng FKBP12-rapamycin- associated protein or mammalian target of rapamycin (FRAP/mTOR) localization in the endoplasmic reticulum and the Golgi apparatus J Biol Chem 279 2004 772 778
25. X. Zhang, L. Shu, H. Hosoi, K.G. Murti, and P.J. Houghton Predominant nuclear localization of mammalian target of rapamycin in normal and malignant cells in culture J Biol Chem 277 2002 28127 28134
26. R.A. Bachmann, J.H. Kim, A.L. Wu, I.H. Park, and J. Chen A nuclear transport signal in mammalian target of rapamycin is critical for its cytoplasmic signaling to S6 kinase 1 J Biol Chem 281 2006 7357 7363
27. D.M. Sabatini MTOR and cancer: insights into a complex relationship Nat Rev Cancer 6 2006 729 734
28. F. Rojo, L. Najera, and J. Lirola 4E-binding protein 1, a cell signaling hallmark in breast cancer that correlates with pathologic grade and prognosis Clin Cancer Res 13 2007 81 89
29. R.L. Yamnik, A. Digilova, and D.C. Davis S6 kinase 1 regulates estrogen receptor alpha in control of breast cancer cell proliferation J Biol Chem 284 2009 6361 6369
30. T. Murayama, M. Inokuchi, and Y. Takagi Relation between outcomes and localisation of p-mTOR expression in gastric cancer Br J Cancer 100 2009 782 788